AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Prostate Choice decision aid
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03182998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03737630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
Study NCT03737630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
Study NCT00467402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine
Study NCT00467402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00661544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
Study NCT00661544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.
Study NCT00661544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
Study NCT03371277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical visit for specific questionnaires
Description: Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
Study NCT03613636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunospot (ELISpot) assay [Blood]
Description: The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].
Study NCT02580175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded evacuation
Description: Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
Study NCT02580175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evacuation under ultrasound guidance
Description: Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
Study NCT04410809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-46
Description: Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
Study NCT04410809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same composition as the active medication but without the active substance TA-46
Study NCT02345915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Study NCT02345915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Study NCT02717442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104
Study NCT02717442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study NCT00542100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCMRI
Study NCT01383447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given PO
Study NCT01383447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT01383447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT01383447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT01752764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product: Salad with a high dosage fat
Study NCT01752764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product: Salad with a high dosage fat
Study NCT01026337 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Description: Correlative study
Study NCT01026337 — intervention group
Intervention type: OTHER
Intervention: pharmacological study
Description: Correlative study
Study NCT01752764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control product: Salad with low dosage fat
Study NCT01752764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control product: Salad with low dosage fat
Study NCT02561208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention Group
Description: Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
Study NCT01783158 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagoscopy and chromoendoscopy
Description: Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy.
Study NCT00765154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir
Description: two 400mg tablets (800mg) once daily
Study NCT00765154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: one 100mg capsule once daily
Study NCT00412880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion
Study NCT04266353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV)
Description: Participants will receive Resveratrol at 150 mg daily for 6 weeks.
Study NCT02830542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-262
Description: SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
Study NCT02830542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Study NCT02239744 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Air purifiers
Description: The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
Study NCT02239744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purifiers
Description: The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
Study NCT03784781 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biopsy
Description: Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
Study NCT03784781 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Blood collection (+15mL/ current care)
Study NCT03784781 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage fluid (3mL/Kg)
Study NCT00541671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 c of saline
Study NCT00541671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: Physician ordered dose
Study NCT02165397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive 420 mg of Ibrutinib orally.
Study NCT02165397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo capsules orally.
Study NCT01026337 — intervention group
Intervention type: PROCEDURE
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT01026337 — intervention group
Intervention type: DRUG
Intervention: sunitinib malate
Description: Given orally
Study NCT01026337 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Description: Correlative study
Study NCT01026337 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT02771925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 2g/day divided in two doses for 24 weeks
Description: Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment.
Study NCT02771925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2g/day divided in two doses for 24 weeks
Description: Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
Study NCT03528564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
Study NCT03528564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron sucrose
Description: Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
Study NCT03528564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
Study NCT03528564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
Study NCT02470663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DENSITYTM caplets (marketed as Amorphical)
Description: supplementation
Study NCT02470663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate 600 mg once daily
Description: supplementation
Study NCT03268005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Study NCT03268005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Study NCT03268005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Study NCT03268005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Study NCT03268005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Study NCT03268005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Study NCT02165397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab 375 mg/m\^2 IV.
Study NCT01855477 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Histological biopsy procedure
Study NCT00210678 — intervention group
Intervention type: BEHAVIORAL
Intervention: No intervention
Description: No treatment is given to the patients as this is an observational study.
Study NCT04059887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
Study NCT04199455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)
Description: Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day.
Study NCT04199455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day.
Study NCT02226497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use home telemonitoring device
Study NCT02226497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02226497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02226497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02226497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02226497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Receive standard outpatient supportive care
Study NCT02226497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive standard outpatient supportive care
Study NCT03962517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with Gait Enhancing and Motivating System-Hip (GEMS-H)
Description: The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living.
Study NCT03962517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without Gait Enhancing and Motivating System-Hip (GEMS-H)
Description: The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
Study NCT03587519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early
Description: Early ileostomy closure
Study NCT03587519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late
Description: Late ileostomy closure
Study NCT03526978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational sIPV
Description: Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
Study NCT03526978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control IPV
Description: Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
Study NCT01184534 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video
Description: 5 minute multimedia presentation (video)
Study NCT01184534 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
Study NCT04546022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.